What Parents Need to Know About Moles in Children - Scorecard - MDSpire

What Parents Need to Know About Moles in Children

  • By

  • E. Meryl Shychuk

  • Elyse M. C. Harris

  • Lindsay A. Thompson

  • May 1, 2026

Share

Clinical Scorecard: Essential Information for Parents Regarding Childhood Moles

At a Glance

CategoryDetail
ConditionChildhood Moles
Key MechanismsSkin growths made of pigment cells; potential to develop into melanoma.
Target PopulationChildren, particularly those with changing moles.
Care SettingPediatric and dermatological care.

Key Highlights

  • Most moles are harmless but require monitoring for changes.
  • Signs of concern include rapid growth, color change, and irregular borders.
  • Preventive measures include sun protection and regular dermatological evaluations.

Guideline-Based Recommendations

Diagnosis

  • Evaluate moles for size, shape, color, and changes over time.

Management

  • Refer to a dermatologist for moles that exhibit concerning changes.

Monitoring & Follow-up

  • Regularly check moles, especially congenital and dysplastic nevi.

Risks

  • Increased risk of melanoma with certain mole characteristics.

Patient & Prescribing Data

Children with moles, especially those with atypical features.

Early detection and monitoring are crucial for effective management.

Clinical Best Practices

  • Educate parents on the characteristics of benign vs. concerning moles.
  • Encourage sun safety practices to reduce skin cancer risk.

References

Original Source(s)

What Parents Need to Know About Moles in Children

  • by E. Meryl Shychuk, Elyse M. C. Harris, Lindsay A. Thompson

  • May 1, 2026

Related Content

Primary cutaneous adenoid cystic carcinoma of the right forearm: a case report and dermoscopic features

AI Model Trails Expert Skin Lesion Readers

A foundation artificial intelligence model surpassed less experienced physicians but did not outperform expert dermatologists in multiclass skin lesion diagnosis.

Pilot study of topical imiquimod combined with pembrolizumab for unresectable cutaneous metastatic melanoma